<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-12-76-a</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-12-10-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Antiepileptic Drugs</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Carbamazepine Exacerbation of Absence Epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>10</month>
<year>1998</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>05</month>
<year>2016</year>
</pub-date>
<volume>12</volume>
<issue>10</issue>
<fpage>76</fpage>
<lpage>76</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1998 The Author(s)</copyright-statement>
<copyright-year>1998</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1111/j.1469-8749.1998.tb15409.x" vol="40" page="517">
<article-title>Inappropriate use of carbamazepine and vigabatrin in typical absence seizures</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>The inappropriate use of carbamazepine (CBZ) in 8 children, and vigabatrin (VGB) in 2, among 18 consecutive referrals of children with resistant typical absence seizures, is reported from St Thomas&#x2019; and Guy&#x2019;s Hospitals, London, UK.</p>
</abstract>
<kwd-group>
<kwd>Carbamazepine Exacerbation of Absence Seizures</kwd>
<kwd>Myoclonic Epilepsies</kwd>
<kwd>Sodium Valproate</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The inappropriate use of carbamazepine (CBZ) in 8 children, and vigabatrin (VGB) in 2, among 18 consecutive referrals of children with resistant typical absence seizures, is reported from St Thomas&#x2019; and Guy&#x2019;s Hospitals, London, UK. Frequency of absences had increased in 4 of the children who received CBZ and 2 of these developed myoclonic jerks in addition, which resolved after CBZ withdrawal. Typical absence epilepsy was confirmed by EEG, video-EEG, or both. Subsequent control of seizures was obtained with valproate, lamotrigine, or ethosuximide. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<p>COMMENT. Carbamazepine and vigabatrin may exacerbate or induce typical absence seizures. These AEDs are also contraindicated in myoclonic epilepsies. Patients with absence seizures who fail to respond to sodium valproate or ethosuximide should be treated with either lamotrigine, acetazolamide, or clonazepam. The inappropriate second choice of CBZ or VGB after VPA failure in the patients referred above was unexplained, but misdiagnosis as partial seizures was a possible reason. EEG correlation or video-EEG is essential in arriving at a correct diagnosis. Although the carbamazepine exacerbation of absence seizures has been known since 1974 (Cereghino et al), this report from London and that from Switzerland suggest that clinicians are not sufficiently aware of the hazards of inappropriate use of AEDs.</p>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Agathonikou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Panayiotopoulos</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>Inappropriate use of carbamazepine and vigabatrin in typical absence seizures</article-title>
<source>Dev Med Child Neurol</source>
<year>1998</year>
<month>Aug</month>
<volume>40</volume>
<issue>8</issue>
<fpage>517</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1998.tb15409.x</pub-id>
<pub-id pub-id-type="pmid">9746003</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>